Immunic, Inc. Common Stock IMUX
i
Market datapartial · fetched 2026-11-12T15:29:13.433Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:25:11.499081279Z
FundamentalsAlpha Vantage · unavailable
Immunic, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.53 | 305.3% | 33.1% | |||
| 25Δ | 21.28 | 603.1% | 187.4% | 5.98 | 267.1% | 27.7% |
| 30Δ | 18.43 | 599.1% | 152.4% | 6.43 | 229.0% | 22.2% |
| 35Δ | 6.88 | 190.9% | 16.7% | |||
| 40Δ | 7.33 | 152.8% | 11.2% | |||
| 45Δ | 8.74 | 244.8% | 24.8% | 7.77 | 149.7% | 8.8% |
| 50Δ | 8.31 | 241.3% | 20.5% | 8.20 | 168.2% | 8.1% |
| 55Δ | 7.87 | 237.8% | 16.3% | 8.64 | 186.8% | 7.5% |
| 60Δ | 7.43 | 237.2% | 12.5% | 9.08 | 205.4% | 6.9% |
| 65Δ | 6.98 | 252.0% | 10.9% | 9.51 | 224.0% | 6.3% |
| 70Δ | 6.53 | 266.9% | 9.3% | 9.95 | 242.5% | 5.6% |
| 75Δ | 6.09 | 281.8% | 7.8% | |||
| 80Δ | 5.64 | 296.7% | 6.2% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.53
- IV
- 305.3%
- B/E move
- 33.1%
25Δ
- Pseudo strike
- 21.28
- IV
- 603.1%
- B/E move
- 187.4%
- Pseudo strike
- 5.98
- IV
- 267.1%
- B/E move
- 27.7%
30Δ
- Pseudo strike
- 18.43
- IV
- 599.1%
- B/E move
- 152.4%
- Pseudo strike
- 6.43
- IV
- 229.0%
- B/E move
- 22.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.88
- IV
- 190.9%
- B/E move
- 16.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.33
- IV
- 152.8%
- B/E move
- 11.2%
45Δ
- Pseudo strike
- 8.74
- IV
- 244.8%
- B/E move
- 24.8%
- Pseudo strike
- 7.77
- IV
- 149.7%
- B/E move
- 8.8%
50Δ
- Pseudo strike
- 8.31
- IV
- 241.3%
- B/E move
- 20.5%
- Pseudo strike
- 8.20
- IV
- 168.2%
- B/E move
- 8.1%
55Δ
- Pseudo strike
- 7.87
- IV
- 237.8%
- B/E move
- 16.3%
- Pseudo strike
- 8.64
- IV
- 186.8%
- B/E move
- 7.5%
60Δ
- Pseudo strike
- 7.43
- IV
- 237.2%
- B/E move
- 12.5%
- Pseudo strike
- 9.08
- IV
- 205.4%
- B/E move
- 6.9%
65Δ
- Pseudo strike
- 6.98
- IV
- 252.0%
- B/E move
- 10.9%
- Pseudo strike
- 9.51
- IV
- 224.0%
- B/E move
- 6.3%
70Δ
- Pseudo strike
- 6.53
- IV
- 266.9%
- B/E move
- 9.3%
- Pseudo strike
- 9.95
- IV
- 242.5%
- B/E move
- 5.6%
75Δ
- Pseudo strike
- 6.09
- IV
- 281.8%
- B/E move
- 7.8%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.64
- IV
- 296.7%
- B/E move
- 6.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 103.14% | |
| 163.28% | |
| 149.96% | |
| 88.56% | |
| 90.43% | |
| 93.50% | |
| 110.52% | |
| 103.10% | |
| 99.26% | |
| 108.10% | |
| 93.04% | |
| 98.56% | |
| 134.13% | |
| 118.66% | |
| 157.09% | |
| 168.40% | |
| 151.60% | |
| 161.33% | |
| 226.04% | |
| 152.38% | |
| 254.74% | |
| 143.32% | |
| 123.10% | |
| 142.13% | |
| 148.36% | |
| 171.70% | |
| 156.12% | |
| 138.94% | |
| 135.19% | |
| 166.78% | |
| 179.57% | |
| 280.00% | |
| 277.23% | |
| 223.82% | |
| 224.94% | |
| 206.50% | |
| 235.09% | |
| 195.06% | |
| 233.57% |
Biotechnology
IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York,…
More →INBX
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla,…
More →INCY
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
More →INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic…
More →INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases…
More →INSM
Description unavailable
More →